MedTrace Logo

PyroTITAN Humeral Resurfacing Arthroplasty (HRA)

NCT02983292 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 137

Last updated 2024-11-04

Study results available
· View outcomes & findings →

Summary

The study is designed as a single center, post-market, non-randomized, open-label, observational clinical study with retrospective and prospective enrollment to evaluate the 2-year post implantation survivorship of the PyroTITAN™ HRA device following the implementation of a new proof test to identify and eliminate devices with sub-standard mechanical integrity.

Conditions

Interventions

DEVICE

PyroTITAN™ HRA

Humeral Resurfacing

Sponsors & Collaborators

  • Smith & Nephew, Inc.

    lead INDUSTRY

Principal Investigators

  • Belinda Larson · Smith & Nephew, Inc.

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2023-02-08
Completion
2023-02-08

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02983292 on ClinicalTrials.gov